Please login to the form below

overactive bladder

This page shows the latest overactive bladder news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding

Urovant Sciences has licensed a novel gene therapy for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy. ... There are no currently available FDA-approved gene therapy treatments for overactive bladder.

Latest news

Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

The proceeds will fund phase III trials of its overactive bladder treatment candidate vibegron, which it in-licensed last year from Merck &Co. ... Urovant aims to investigate the drug’s use in overactive bladder (OAB), as well as another trial in OAB
Allergan pushes on with Botox for depression

overactive in depression. ... Aside from its use as a wrinkle treatment Botox is already approved to treat various medical conditions, including chronic migraine, excessive sweating and overactive bladder among others, and is Allergan's
Size matters?

Clinical trials are ongoing to test its application against overactive bladder and migraine.
Astellas sells dermatology unit to Leo for €675m

The overarching aim is to prepare for the forthcoming patent expiries on big-selling drugs Vesicare (solifenacin succinate) for overactive bladder and cancer therapy Tarceva (erlotinib).
Eylea's UK launch earns Bayer PMEA success

strategy. Other companies recognised in the category included Astellas, which was highly commended for its launch of overactive bladder treatment Betmiga, while Astellas and Shire were both finalists.

More from news
Approximately 4 fully matching, plus 46 partially matching documents found.

Latest Intelligence

Astellas: Ten years young

In Europe we have been launching a product almost every single year,” notes Ken, pointing to products such as the overactive bladder (OAB) drug Betmiga (mirabegron) - the first of a new
Allergan and taking a specialised approach

In addition to migraine and adult spasticity, its approved indications include overactive bladder, muscle stiffness in elbow, wrist and fingers, muscle problems in the eye, crow's feet lines and severe
Interview: Kay Drake and Naoki Okamura, Astellas

For example, we are a GCL in urology; we have Vesicare, which has 40 per cent market share in the overactive bladder (OAB) market. ... From an OAB perspective, we support the Bladder and Bowel Foundation here in the UK, which provides a patient advice
Interview: Ken Jones, Astellas Pharma Europe

Urology is a key strategic area for Astellas and we have a strong pipeline in this therapy area; we are currently getting prepared with Mirabegron, a drug to treat overactive bladder,

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

emotive boosts health economics and outcomes research team

His MSc project involved performing a health economic evaluation of the cost-effectiveness of different overactive bladder treatments available in the UK. ... The appointment of Trishal, with his specific expertise in visual science and overactive bladder

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Medical Writer (Remote Working): Competitive Salary Offered

Medical/ Scientific Director: Salary TBC

Associate Editorial Director – Med Comms – London: Salary TBC

Account Director: Excellent benefits

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Consultant Health Economics - London / Oxford: Negotiable

Senior Account Director development role to Business Director, H...: Excellent package

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

Associate Director, Market Access & HEOR – North-West: Negotiable

Medical Writers: Competitive Salary and Benefits

Director, Market Access / HEOR - North-West: Negotiable

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Senior Medical Writer: Great salary and benefits

Senior Account Executive, London, Medical Communications: Excellent package

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Project / Account Manager (Medical Education): Salary TBC

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Associate Director: £75, 000-90, 000

Production Manager – Healthcare Communications: DOE

Associate Medical Director: Highly Competitive

Subscribe to our email news alerts

PMHub

Add my company

Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

Innovation in merger control and the impact on the pharmaceutical sector: Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think: Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Quality in Care Diabetes 2018: the best in innovative diabetes care: Awards highlight new evidence-based approaches to improving care...